Learn more about whether Biogen Inc. or Gilead Sciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) (OTCPK:ESAIY) announced that the U.S. Food and Drug Administration (FDA) accepted a marketing application for an injectable version of their Alzheimer ...

Biogen does not undertake any obligation to publicly update any forward-looking statements. LEQEMBI (lecanemab-irmb) injection, for intravenous use [package insert]. Nutley, NJ: Eisai Inc ...

Biogen and Eisai’s Alzheimer’s disease (AD) drug Leqembi (lecanemab-irmb) has been approved by the US Food and Drug ...

Biogen and Eisai have announced that the US Food and Drug ... maintenance dosing in patients who have completed the bi-weekly IV initiation phase, with the injection process expected to take 15 ...

The injection process is expected to take ... s development and regulatory submissions globally. Eisai and Biogen co-commercialize and co-promote the product, and Eisai has the final decision ...

Learn more about whether Catalyst Pharmaceuticals, Inc. or Ionis Pharmaceuticals, Inc. is a better investment based on AAII's ...

Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...

The cash injection comes as Biogen has been hit hard by the stalled rollout of its Alzheimer's disease drug Aduhelm (aducanumab), with Stat reporting earlier this month that the company is ...

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with ...